Effects of Ziyin Jianghuo Ningxin decoction plus dehydroepiandrosterone and femoston in treatment of patients with menopausal symptoms

作     者：Lin Jing Zhu Jun Tian Fubo Chen Lanting Zhang Yang Wang Yan Wang Mingyan Hans-Jurgen Gober Li Da-jin Wang Ling 

作者机构：Laboratory for Reproductive ImmunologyHospital &Institute of Obstetrics and GynecologyIBSShanghai Medical CollegeFudan UniversityShanghai 200032China Shanghai Key Laboratory of Female Reproductive Endocrine-related DiseasesShanghai 200011China The Academy of Integrative Medicine of Fudan Uni-versityShanqhai 200032China Department of Obstetrics and GynecologyWen-ling People's HospitalWenzhou Medical UniversityWenling 317500China Heilongjiang University of Chinese MedicineHeilongjiang 150040China Department of PharmacyKepler University ClinicNeuromed CampusLinzAustria 

出 版 物：《Journal of Traditional Chinese Medicine》 (中医杂志（英文版）)

年 卷 期：2018年第38卷第5期

页      面：787-796页

核心收录：

学科分类：10[医学] 

基　　金：Supported by the National Natural Science Foundation of China(No.31571196) the Science and Technology Commission of Shanghai Municipality 2015 YIXUEYINGDAO project(No.15401932200) the FY2008 JSPS Postdoctoral Fellowship for Foreign Researchers P08471 the National Natural Science Foundation of China(No.30801502) the Shanghai Pujiang Program(No.11PJ1401900) Development Project of Shanghai Peak Disciplines-Integrative Medicine(No.20150407) 

主　　题：Menopausal symptoms Menopausal hormone therapy Femoston,Ziyin Jianghuo Ningxin Decoction Dehydroepiandrosterone 

摘      要：OBJECTIVE: To determine the therapeutic effect of Ziyin Jianghuo Ningxin Decoction(ZYJHNXD) plus dehydroepiandrosterone(DHEA) and menopausalhormone therapy(MHT) in patients suffering from menopausal symptoms identified as, in terms of Traditional Chinese Medicine, symptom pattern of Yin deficiency with hyperactive ***: Totally 180 postmenopausal women aged 40 to 60 years were assigned into four groups and accepted femoston, femoston with ZYJHNXD,femoston with DHEA, femoston with ZYJHNXD and DHEA therapies, respectively, for three *** questionnaire-based measure instruments included modified Kupperman index(MKI),Hamilton Rating Scale for Anxiety(HAMA), and Hamilton Rating Scale for Depression(HAMD). Follicle-stimulating hormone(FSH), luteinizing hormone(LH), estradiol(E2), 5-hydroxyindole-3-acetic acid(5-HIAA), norepinephrine(NE), dopamine(DA),bone mineral density(BMD), and sleep quality were evaluated before and three months after the ***: In all four groups, the scores of MKI, HAMA, HAMD and the levels of FSH, LH decreased significantly(P 0.05) after the treatment, while the levels of E2, 5-HIAA, NE, and DA showed obvious elevation(P 0.05). The group receiving ZYJHNXD and DHEA combined with femoston had superiority in the preservation of bone mineral density and improvement of total sleep time and nighttime sleep time over the other three ***: ZYJHNXD and DHEA combined with MHT therapy have a favorable outcome in managing menopausal symptoms, restoring hormone levels, preventing skeletal rarefaction or osteoporosis,and improving sleep quality for postmenopausal women.